Journal
PHARMACEUTICAL RESEARCH
Volume 30, Issue 12, Pages 3101-3113Publisher
SPRINGER/PLENUM PUBLISHERS
DOI: 10.1007/s11095-013-1145-x
Keywords
bioavailability; cinnarizine; lipolysis; oral drug delivery; self-nanoemulsifying drug delivery systems
Funding
- AstraZeneca Pharmaceuticals (Sweden)
- AstraZeneca Pharmaceuticals (UK)
Ask authors/readers for more resources
To investigate the effect of increasing the loading level of the poorly soluble drug cinnarizine in a self-nanoemulsifying drug delivery system (SNEDDS) both in vitro and in vivo. A fixed dose of cinnarizine was administered orally to dogs in solution in different amounts of SNEDDS vehicle. Furthermore, the SNEDDSs were characterised using the dynamic in vitro lipolysis model. Statistical differences in bioavailability were not obtained between the different amounts of SNEDDS vehicle, in spite of differences in the tendency of cinnarizine to precipitate during in vitro lipolysis of the treatments. Use of the SNEDDS concept decreased the variation in cinnarizine exposure observed between dogs as compared to administering cinnarizine in an aqueous suspension. Optimization of SNEDDSs towards keeping the drug compound in solution upon in vitro lipolysis of the SNEDDSs may not be as important as previously suggested.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available